Literature DB >> 2058260

Secretory immune responses in the mouse vagina after parenteral or intravaginal immunization with an immunostimulating complex (ISCOM).

M A Thapar1, E L Parr, J J Bozzola, M B Parr.   

Abstract

Immunostimulating complexes (ISCOMs) are subunit vaccines that are particularly effective in producing immunity against systemic viral infections, but their effectiveness against mucosal infections has received little attention. To study their ability to produce mucosal immune responses in the female reproductive tract, a model ISCOM was prepared containing sheep erythrocyte membrane proteins, and anti-erythrocyte IgA and IgG titres in mouse vaginal washings were measured after immunization at parenteral or local mucosal sites. The ISCOM was prepared by a modified procedure that resulted in incorporation of 10-15% of initial membrane protein compared with 1-5% previously reported. Electrophoretic analysis demonstrated that four out of five erythrocyte membrane proteins were incorporated into the ISCOM, and electron microscopic observations indicated that the ISCOM had a cage-like structure with a diameter of 40 nm, similar to previous ISCOMs. Immunization in the pelvic presacral space (p.s.-p.s.) stimulated significantly higher anti-erythrocyte IgA titres in vaginal fluid than were produced by intraperitoneal (i.p.-i.p.), subcutaneous (s.c.-s.c.), intravaginal (i.vag.-i.vag.), or i.p.-i.vag. immunizations with the same vaccine. Specific IgG titres were less dependent on the route of immunization, with p.s.-p.s., i.p.-i.p. and s.c.-s.c. administration all giving similar high titres while i.p.-i.vag. treatment induced lower titres. These observations using a model ISCOM indicate that mucosal immune responses against membrane proteins were elicited in the female reproductive tract, and that non-mucosal immunization in the pelvis was a more effective route of administration than local application of the ISCOM to the vaginal mucosa.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2058260     DOI: 10.1016/0264-410x(91)90269-c

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  14 in total

1.  Localization of a domain in the FimH adhesin of Escherichia coli type 1 fimbriae capable of receptor recognition and use of a domain-specific antibody to confer protection against experimental urinary tract infection.

Authors:  K Thankavel; B Madison; T Ikeda; R Malaviya; A H Shah; P M Arumugam; S N Abraham
Journal:  J Clin Invest       Date:  1997-09-01       Impact factor: 14.808

2.  Specific-antibody-secreting cells in the rectums and genital tracts of nonhuman primates following vaccination.

Authors:  K Eriksson; M Quiding-Järbrink; J Osek; A Möller; S Björk; J Holmgren; C Czerkinsky
Journal:  Infect Immun       Date:  1998-12       Impact factor: 3.441

3.  Induction of protection against vaginal shedding and infertility by a recombinant Chlamydia vaccine.

Authors:  Jennifer R Carmichael; Sukumar Pal; Delia Tifrea; Luis M de la Maza
Journal:  Vaccine       Date:  2011-05-24       Impact factor: 3.641

Review 4.  Nasal lymphoid tissue, intranasal immunization, and compartmentalization of the common mucosal immune system.

Authors:  H Y Wu; M W Russell
Journal:  Immunol Res       Date:  1997       Impact factor: 2.829

Review 5.  Mucosal HIV transmission and vaccination strategies through oral compared with vaginal and rectal routes.

Authors:  Mingke Yu; Michael Vajdy
Journal:  Expert Opin Biol Ther       Date:  2010-08       Impact factor: 4.388

6.  Use of cellular depletion analysis to examine circulation of immune effector function between the vagina and the periphery.

Authors:  P L Fidel; W Luo; J Chabain; N A Wolf; E Van Buren
Journal:  Infect Immun       Date:  1997-09       Impact factor: 3.441

Review 7.  Update on Chlamydia trachomatis Vaccinology.

Authors:  Luis M de la Maza; Guangming Zhong; Robert C Brunham
Journal:  Clin Vaccine Immunol       Date:  2017-04-05

Review 8.  Immunopathogenesis of recurrent vulvovaginal candidiasis.

Authors:  P L Fidel; J D Sobel
Journal:  Clin Microbiol Rev       Date:  1996-07       Impact factor: 26.132

9.  Immunogenicity of influenza and HSV-1 mixed antigen ISCOMs in mice.

Authors:  H O Ghazi; M Erturk; L M Stannard; M Faulkner; C W Potter; R Jennings
Journal:  Arch Virol       Date:  1995       Impact factor: 2.574

10.  Intranasal immunization of mice with herpes simplex virus type 2 recombinant gD2: the effect of adjuvants on mucosal and serum antibody responses.

Authors:  M Ugozzoli; D T O'Hagan; G S Ott
Journal:  Immunology       Date:  1998-04       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.